Strong Launches Will Help BMS Win The LOE Battle In 2023 And Beyond
Three New Drugs Reached US Market In 2022
Bristol Myers Squibb brought the last of nine new drugs to market last year – all needed to help it overcome three big losses of exclusivity this decade – so the focus this year is commercial execution.
You may also be interested in...
Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum
Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.
Bristol’s Boerner To Succeed CEO Caforio With Launch Execution In The Spotlight
Giovanni Caforio will step down as CEO of Bristol Myer Squibb effective 1 November, with chief commercialization officer Boerner primed to succeed him.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Amgen launches first US biosimilar to Humira; strong launches set to help BMS as it faces losses of exclusivity; Eisai preaches patience on Leqembi for Alzheimer’s; 10 clinical trials to watch for this year; and Scrip Asks what 2023 holds in store for biopharma technological advances.